Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 3/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 2/20 | 0.33 |
| ▸ | PDE8B | O95263 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | EBP | Q15125 | 2/20 | 0.32 |
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
| ▸ | CTSE | P14091 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | TACR2 | P21452 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4227086 | 0.82 | CHRM5 (0.45) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL2687447 | 0.78 | AOC3 (0.34) | AOC3GRM5GBA1PDE8BTACR2 | |
| SCHEMBL4702124 | 0.75 | CYP3A4 (0.38) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL3816674 | 0.75 | CYP3A4 (0.38) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL2686629 | 0.71 | PDE8B (0.33) | PDE8BCYP11B2CTSDCTSEBACE1 | |
| SCHEMBL2688471 | 0.71 | CTSD (0.39) | MAPTPDE8BCYP11B2CTSDCTSE | |
| SCHEMBL14143578 | 0.71 | GAA (0.49) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL6258023 | 0.71 | CYP3A4 (0.45) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL14170365 | 0.70 | EBP (0.32) | CYP11B2EBPBRD4 | |
| SCHEMBL29779388 | 0.70 | KDM4E (0.47) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079727-B1 | KINASE INHIBITOR COMPOUNDS | XCOVERY INC (US) | 2016-02-17 | — | — | EP | claimed |
| US-8524709-B2 | Kinase inhibitor compounds | TYROGENEX, INC. (US) | 2013-09-03 | — | — | US | claimed |
| US-20120115866-A1 | KINASE INHIBITOR COMPOUNDS | TYROGENEX, INC. (US) | 2012-05-10 | — | — | US | claimed |
| US-7683057-B2 | 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (1-acetyl-piperidin-4-yl)-amide; inhibition of 5' AMP-activated protein kinase (AMPK) | TYROGENEX, INC. (US) | 2010-03-23 | — | — | US | claimed |
| US-20090076005-A1 | Kinase inhibitor compounds | XCOVERY, INC. (US) | 2009-03-19 | — | — | US | claimed |
| EP-2079727-B1 | KINASE INHIBITOR COMPOUNDS | XCOVERY INC (US) | 2016-02-17 | — | — | EP | disclosed |
| US-8524709-B2 | Kinase inhibitor compounds | TYROGENEX, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120115866-A1 | KINASE INHIBITOR COMPOUNDS | TYROGENEX, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20100261665-A1 | Kinase inhibitor compounds | XCOVERY, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-7683057-B2 | 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (1-acetyl-piperidin-4-yl)-amide; inhibition of 5' AMP-activated protein kinase (AMPK) | TYROGENEX, INC. (US) | 2010-03-23 | — | — | US | disclosed |
| EP-2079727-A2 | KINASE INHIBITOR COMPOUNDS | Xcovery, INC. (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20090076005-A1 | Kinase inhibitor compounds | XCOVERY, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| WO-2008033562-A2 | KINASE INHIBITOR COMPOUNDS | XCOVERY, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076005-A1 | Kinase inhibitor compounds | MAP3K1, MAP3K20, MAP3K2 | CYP3A4 4408/4885TSHR 4114/4885TDP1 794/4885 |
| US-20120115866-A1 | KINASE INHIBITOR COMPOUNDS | MAP3K1, MAP3K20, MAP3K2 | CYP3A4 4408/4885TSHR 4114/4885TDP1 794/4885 |
| US-20100261665-A1 | Kinase inhibitor compounds | MAP3K1, MAP3K20, MAP3K2 | CYP3A4 4408/4885TSHR 4114/4885TDP1 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.